Yagi Masahiro, Nakao Koichi, Honda Takashi, Tsurumi Yukio, Kasanuki Hiroshi
The Cardiovascular Center, Saiseikai Kumamoto Hospital, 5-3-1 Chikami, Kumamoto 861-4193, Japan.
Int J Cardiol. 2004 Mar;94(1):41-6. doi: 10.1016/j.ijcard.2003.03.019.
Not much data is available regarding "real-world" clinical experience of very elderly patients with acute myocardial infarction (AMI) in the reperfusion era.
We reviewed 483 patients (26%) between the ages of 75 and 85 from the 1855 patients with AMI. We analyzed 264 patients treated with reperfusion therapy (55%) and 219 patients treated with conservative therapy (45%) on their clinical characteristics and early outcomes.
Patients treated with reperfusion therapy were slightly younger (79.0 vs. 80.0 years, P=0.01), presented earlier (205 vs. 400 minutes, P<0.01) and had higher peak creatine kinase values (2634 vs. 1407 IU/l, P<0.01) than those treated with conservative therapy. Other clinical profiles including sex, prior myocardial infarction, hypertension, diabetes, and infarct location were similar to each other. There was a 92% success for reperfusion therapy. The incidence of recurrent ischemia, cardiac rupture, and cerebral hemorrhage was not significantly different between the two groups. In-hospital mortality in this study was 20.5%. In-hospital mortality was not significantly different between the two groups (19% vs. 23%, P=0.25). The multivariate analysis showed that age, infarct location, and Killip class were correlated to in-hospital mortality. The leading cause of in-hospital death was pump failure.
Older age and late presentation were correlated to conservative therapy in very elderly patients with AMI. Early outcomes were similar between the two treatment groups. In-hospital mortality seemed to be associated with impaired myocardial reserve.
关于再灌注时代高龄急性心肌梗死(AMI)患者的“真实世界”临床经验,可用数据不多。
我们从1855例AMI患者中回顾了483例年龄在75至85岁之间的患者(占26%)。我们分析了264例接受再灌注治疗的患者(占55%)和219例接受保守治疗的患者(占45%)的临床特征和早期结局。
与接受保守治疗的患者相比,接受再灌注治疗的患者年龄稍小(79.0岁对80.0岁,P=0.01),就诊时间更早(205分钟对400分钟,P<0.01),肌酸激酶峰值更高(2634 IU/l对1407 IU/l,P<0.01)。其他临床特征,包括性别、既往心肌梗死、高血压、糖尿病和梗死部位,两组之间相似。再灌注治疗成功率为92%。两组之间复发性缺血、心脏破裂和脑出血的发生率无显著差异。本研究中的住院死亡率为20.5%。两组之间的住院死亡率无显著差异(19%对23%,P=0.25)。多因素分析显示,年龄、梗死部位和Killip分级与住院死亡率相关。住院死亡的主要原因是泵衰竭。
高龄和就诊延迟与高龄AMI患者的保守治疗相关。两个治疗组的早期结局相似。住院死亡率似乎与心肌储备受损有关。